These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22130019)

  • 1. [Adaptive immunity to Aβ amyloid peptide in Alzheimer's disease: lessons and perspectives].
    Dorothée G; Aucouturier P
    Med Sci (Paris); 2011 Nov; 27(11):938-40. PubMed ID: 22130019
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current trend of immunotherapy for Alzheimer's disease].
    Matsumoto SE; Tabira T
    Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease.
    Lannfelt L; Pettersson FE; Nilsson LN
    Nutr Rev; 2010 Dec; 68 Suppl 2():S128-34. PubMed ID: 21091946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
    Schenk DB; Seubert P; Grundman M; Black R
    Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.
    Nemirovsky A; Fisher Y; Baron R; Cohen IR; Monsonego A
    Vaccine; 2011 May; 29(23):4043-50. PubMed ID: 21473952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models.
    Busche MA; Grienberger C; Keskin AD; Song B; Neumann U; Staufenbiel M; Förstl H; Konnerth A
    Nat Neurosci; 2015 Dec; 18(12):1725-7. PubMed ID: 26551546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.
    Blasko I; Grubeck-Loebenstein B
    Drugs Aging; 2003; 20(2):101-13. PubMed ID: 12534311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-specific adaptive immune biomarkers in Alzheimer's disease and related pathologies.
    Dorothée G; Sarazin M; Aucouturier P
    Rev Neurol (Paris); 2013 Oct; 169(10):715-8. PubMed ID: 24016465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunology and immunotherapy of Alzheimer's disease.
    Weiner HL; Frenkel D
    Nat Rev Immunol; 2006 May; 6(5):404-16. PubMed ID: 16639431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-mediated immunotherapy for Alzheimer's disease.
    Solomon B
    Curr Opin Investig Drugs; 2007 Jul; 8(7):519-24. PubMed ID: 17659471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's amyloid immunotherapy: quo vadis?
    Gandy S; Heppner FL
    Lancet Neurol; 2005 Aug; 4(8):452-3. PubMed ID: 16033686
    [No Abstract]   [Full Text] [Related]  

  • 12. CD4 T cells in immunity and immunotherapy of Alzheimer's disease.
    Monsonego A; Nemirovsky A; Harpaz I
    Immunology; 2013 Aug; 139(4):438-46. PubMed ID: 23534386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune system, amyloid-beta peptide, and Alzheimer's disease.
    Weksler ME; Gouras G; Relkin NR; Szabo P
    Immunol Rev; 2005 Jun; 205():244-56. PubMed ID: 15882358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Solfrizzi V; Pilotto A
    Expert Opin Biol Ther; 2011 Jun; 11(6):679-86. PubMed ID: 21501112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-amyloid immunisation in Alzheimer's disease.
    Sorbi S
    Neurol Sci; 2005 May; 26 Suppl 1():S5. PubMed ID: 15883696
    [No Abstract]   [Full Text] [Related]  

  • 16. Sink hypothesis and therapeutic strategies for attenuating Abeta levels.
    Zhang Y; Lee DH
    Neuroscientist; 2011 Apr; 17(2):163-73. PubMed ID: 21330304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.
    Wang YJ; Zhou HD; Zhou XF
    Drug Discov Today; 2006 Oct; 11(19-20):931-8. PubMed ID: 16997144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-beta immunotherapies in mice and men.
    Brendza RP; Holtzman DM
    Alzheimer Dis Assoc Disord; 2006; 20(2):118-23. PubMed ID: 16772748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active immunization with amyloid-beta 1-42 impairs memory performance through TLR2/4-dependent activation of the innate immune system.
    Vollmar P; Kullmann JS; Thilo B; Claussen MC; Rothhammer V; Jacobi H; Sellner J; Nessler S; Korn T; Hemmer B
    J Immunol; 2010 Nov; 185(10):6338-47. PubMed ID: 20943998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Alzheimer's disease: the beginning of a new era.
    Schenk D
    Curr Alzheimer Res; 2006 Jul; 3(3):177. PubMed ID: 16842091
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.